

**COPY OF PAPERS** ORIGINALLY FILED RECEIVED

AUG 0 9 2002

TECH CENTER 1600/2900

## GARDERE

attorneys and counselors www.gardere.com

Direct: 214-999-4559 Direct Fax: 214-999-3559 eflores@gardere.com

July 31, 2002

**BOX: SEQUENCE** Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Inventors: Andrew D. Ellington, Michael P. Robertson, Kristin A. Marshall Re:

U.S. Patent Application Entitled: ALLOSTERICALLY REGULATED RIBOZYMES

Serial No.: 09/661,658 Filed: September 14, 2000 Priority Date: June 15, 2000 Our File No.: 119927-1021

In regard to the above-referenced mater, we have enclosed the following documents:

Response To Office Action (2 pages); 1.

- Diskette Containing Substitute Computer Readable Form; 2.
- Hard Copy of Substitute Sequence Listing (4 pages); and 3.
- Postcard. 4.

Please file the above-referenced document and return the date-stamped postcard to our office at the above address. A copy of the Preliminary Amendment filed with the Commissioner for Patents is also attached as reference only. It is believed that no additional fees are due. If this is incorrect, the Commissioner is hereby authorized to charge any fees due which may be required by this paper to Deposit Account No. 07-0153.

In the meantime, if you have any questions or comments concerning any of the above, please call the undersigned at your convenience. Otherwise, please accept the enclosed.

If you need anything further, please do not hesitate to contact me.

Sincerely

Edwin S. Flores

Registration No. 38,453

Enclosure

RS	
œ	ш
ũ	_
ā.	ũ.
×	>
ind.	-
肽	7
ō	3
~	Z
>	洒
450	$\simeq$
Ų,	Œ
C	Ō

Notice to Comp	OTP E VOLONIE	Notice to Compl
----------------	---------------	-----------------

Application No.	Applicant(s)
09/661,658 Examiner	Gallagher et al. Art Unit
Janet Epps	1635

E TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS ONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES** 

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

the	e requirements for such a disclosure as set forth in 37 C.F. N. 1.02.	
$\boxtimes$	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking nublished at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).	
	2. This application does not contain, as a separate part of the disclosure on paper copy, a Sequence	
1	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by	
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or a sindicated on the attached copy of the marked -up "Raw Sequence Listing."	
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer roadable form must be submitted as required by 37 C.F.R. 1.825(d).	
Ι.	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).	
	7. Other Applicants did not include the sequence in Figure 1 in the sequence listing.	
	Applicant Must Provide:  Applicant Must Provid	
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its enti-	
	A statement that the content of the paper and computer readable copies are the same and, whe applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) 1.825(d).	ere Ol

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase Patentin Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY